In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
Pineapple pact shows fruits of collaboration on Earth Day
In California, Dole Packaged Foods has partnered with circular design firm Rais Case and Ananas Anam, creator of pineapple-based textile Piñatex®, to tackle pineapple...
Project converting chicken feathers into cultivated chicken meat concludes first phase
In Italy, a research project looking to grow cells from chicken feathers into chicken meat has concluded its first phase by generating a batch...
Vote for sustainability: Bioplastic dummy ballots used to spread voter awareness
In India, IIT Guwahati has developed 3D-printed dummy ballots made of biobased polylactic acid.
Commissioned by the Systematic Voters' Education and Electoral Participation Cell, the...